MX2023005379A - Enlazadores novedosos de dominios de union a antigenos multiespecificos. - Google Patents

Enlazadores novedosos de dominios de union a antigenos multiespecificos.

Info

Publication number
MX2023005379A
MX2023005379A MX2023005379A MX2023005379A MX2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding domains
multispecific antigen
multispecific
novel linkers
Prior art date
Application number
MX2023005379A
Other languages
English (en)
Inventor
Timothy Riley
Zhulun Wang
Darren L Bates
Bram Estes
Fernando Garces
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023005379A publication Critical patent/MX2023005379A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La capacidad de generar una única construcción basada en anticuerpos que pueda reconocer múltiples dianas simultáneamente es fundamental para hacer avanzar muchos candidatos terapéuticos a la clínica. A menudo, esto implica un diseño de proteínas extenso con varios grados de éxito. En el caso de los anticuerpos multiespecíficos, la conducción del emparejamiento HC/LC en la región Fab representa uno de los desafíos más difíciles hasta el momento en el campo de la ingeniería multiespecífica. Aquí se describe el descubrimiento de un nuevo módulo Fab de cadena única que usa un enlazador novedoso entre los dominios VL-CL y VH-CH1 que permitirá aún más la producción de multiespecíficos.
MX2023005379A 2020-11-10 2021-11-09 Enlazadores novedosos de dominios de union a antigenos multiespecificos. MX2023005379A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112119P 2020-11-10 2020-11-10
PCT/US2021/058669 WO2022103773A1 (en) 2020-11-10 2021-11-09 Novel linkers of multispecific antigen binding domains

Publications (1)

Publication Number Publication Date
MX2023005379A true MX2023005379A (es) 2023-05-23

Family

ID=78821254

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005379A MX2023005379A (es) 2020-11-10 2021-11-09 Enlazadores novedosos de dominios de union a antigenos multiespecificos.

Country Status (8)

Country Link
US (1) US20240002545A1 (es)
EP (1) EP4244246A1 (es)
JP (1) JP2023548595A (es)
AU (1) AU2021379598A1 (es)
CA (1) CA3200603A1 (es)
MX (1) MX2023005379A (es)
TW (1) TW202233663A (es)
WO (1) WO2022103773A1 (es)

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
EP2118138A1 (en) 2007-03-12 2009-11-18 Esbatech AG Sequence based engineering and optimization of single chain antibodies
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
CN102838673B (zh) 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
MX2011010159A (es) * 2009-04-02 2011-10-17 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
EP3539988A3 (en) 2010-05-27 2019-12-04 Genmab A/S Monoclonal antibodies against her2
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
DK2794905T3 (da) * 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2020085827A1 (ko) * 2018-10-24 2020-04-30 주식회사 툴젠 조작된 면역 세포
AU2020233876A1 (en) * 2019-03-08 2021-09-23 Amgen Inc. Growth differentiation factor 15 combination therapy

Also Published As

Publication number Publication date
AU2021379598A1 (en) 2023-06-08
EP4244246A1 (en) 2023-09-20
US20240002545A1 (en) 2024-01-04
TW202233663A (zh) 2022-09-01
JP2023548595A (ja) 2023-11-17
CA3200603A1 (en) 2022-05-19
WO2022103773A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
NZ589434A (en) Dual variable domain immunoglobulins and uses thereof
MX2013001900A (es) Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
CY1116376T1 (el) Τρισθενη, διειδικα αντισωματα
RS51908B (en) CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES
DE60226486D1 (de) Selbstanordnende moleküle
MX2016003593A (es) Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
TR201910213T4 (tr) Disülfürle stabilize edilmiş çok değerlikli antikorlar.
NO20052849L (no) Ikke-kompetitiv immunoassay for sma analytter.
PH12014501783A1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
EA200970954A1 (ru) Пентаспецифические антитела, способы их получения и применения
RU2014109557A (ru) Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения
FI3608337T3 (fi) Bispesifisiä t-solua aktivoivia antigeenia sitovia molekyylejä
RS52452B (en) Antibodies and Immunoconjugates and Their Use
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
JP2013235610A5 (es)
MX2023012379A (es) Ensayos de socio de union especifico de plasmon basados en solucion y nanoestructuras metalicas.
EA202091871A1 (ru) Поливалентное антитело
AR116564A1 (es) Moléculas de unión a antígeno biespecíficas con unión trivalente a cd40
EA201691075A1 (ru) Способы оксимной конъюгации с кетон-модифицированными полипептидами
WO2019005640A3 (en) MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME
ECSP10010142A (es) Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas
EA201991353A1 (ru) Двухвалентные антитела, маскированные спирализованными спиралями
WO2019005639A3 (en) MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci